From Ozempic to Retatrutide: How GLP-1 Drugs Evolved Into Multi-Target Metabolic Powerhouses | Research

The takeaway

GLP-1 drugs have evolved from single-receptor agonists into dual and triple-target peptides that produce dramatically greater weight loss and metabolic benefits by hitting multiple hormone pathways simultaneously.

Single → dual → triple receptor targeting
Each generation of incretin-based peptide therapy targets more hormone receptors, producing progressively greater weight loss, glucose control, and cardiovascular protection.

What the researchers found

GLP-1 receptor agonists have evolved from single-target drugs into dual and triple receptor agonists that represent the cutting edge of metabolic therapy. Single GLP-1RAs (semaglutide, liraglutide) effectively lower HbA1c, reduce weight, protect against cardiovascular events, and improve kidney health. Dual agonists like tirzepatide (GLP-1/GIP) produce even greater weight loss and glucose control by activating two incretin pathways simultaneously.

The next frontier is triple agonists — like retatrutide (GLP-1/GIP/glucagon) — which add glucagon receptor activation to increase energy expenditure and fat burning on top of appetite suppression and glucose control. These multi-agonist peptides represent the future direction of incretin-based therapy for both type 2 diabetes and obesity.

Why it matters

This 2024 review captures a pivotal moment in metabolic medicine: the transition from effective single-target GLP-1 drugs to dramatically more powerful multi-agonist peptides. With obesity affecting over 650 million adults globally and type 2 diabetes over 460 million, the progression from single → dual → triple agonists offers progressively greater therapeutic power for conditions that drive cardiovascular disease, kidney failure, and premature death.

The numbers in context

Single, dual, and triple agonists compared · GLP-1, GIP, and glucagon receptors targeted · HbA1c reduction + weight loss + CV protection · Multiple FDA-approved formulations reviewed

How the study worked

Narrative review of currently approved GLP-1 receptor agonists and emerging dual (GLP-1/GIP) and triple (GLP-1/GIP/glucagon) agonists for type 2 diabetes and obesity. Covers mechanisms of action, clinical efficacy, routes of administration, and future directions. NIH-funded research.

Who was studied

Review covering patients with type 2 diabetes and/or obesity treated with incretin-based therapies

What this study cannot tell us

Narrative review without systematic methodology. The abstract does not provide specific efficacy numbers for individual agents. Some dual and triple agonists discussed are still in clinical development and may not achieve approval. The review may not cover all safety concerns equally across the different agent classes.

How to read the evidence

This is a comprehensive narrative review from a well-funded NIH research group published in EClinicalMedicine (a Lancet Discovery Science journal). While it synthesizes high-quality evidence from pivotal trials, it uses narrative rather than systematic review methodology.

When this study was published

Published in 2024, this review captures the most current state of GLP-1 single, dual, and triple agonist development. Highly current and relevant.

The bigger picture

The progression from semaglutide to tirzepatide to retatrutide represents one of the fastest and most impactful evolutions in modern pharmacology. Each generation of multi-agonist peptide produces greater metabolic benefits, potentially bringing pharmacological weight loss closer to the results achieved by bariatric surgery — but with a daily or weekly injection instead.

Questions still open

Is there a ceiling to how many receptors can be targeted before side effects outweigh benefits?
Will triple agonists like retatrutide achieve weight loss comparable to bariatric surgery?
How will the cardiovascular and kidney benefits of dual and triple agonists compare to single GLP-1 drugs in long-term outcomes trials?

Common questions

What's the difference between single, dual, and triple GLP-1 agonists?

Single agonists (semaglutide, liraglutide) target only the GLP-1 receptor. Dual agonists like tirzepatide also activate GIP receptors, producing greater weight loss and glucose control. Triple agonists like retatrutide add glucagon receptor activation to increase fat burning even further. Each step up targets more metabolic pathways simultaneously.

Are dual and triple agonists better than single GLP-1 drugs?

Clinical data suggests they produce greater weight loss and metabolic improvements. Tirzepatide (dual agonist) has outperformed semaglutide in head-to-head trials. Triple agonists like retatrutide are still in clinical trials but early results show even more dramatic weight loss. However, more receptor targets may also mean different side effect profiles.

Read the original research

GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review.

EClinicalMedicine, 75, 102782

View on PubMed ↗Publisher’s paper ↗

Citation

Alfaris, Nasreen; Waldrop, Stephanie; Johnson, Veronica; Boaventura, Brunna; Kendrick, Karla; Stanford, Fatima Cody. (2024). GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review.. EClinicalMedicine, 75, 102782. https://doi.org/10.1016/j.eclinm.2024.102782